Recursion Pharmaceuticals, Inc. Class A Common Stock vs. Twist Bioscience Corporation Common Stock
RXRX
Recursion Pharmaceuticals, Inc. Class A Common Stock
$4.05 +2.02%
VS TWSTTwist Bioscience Corporation Common Stock
$164.60 -0.74%
Twist Bioscience Corporation Common Stock (TWST) comes out ahead, leading on 7 of 8 compared factors.
Size & Scale
| RXRX | TWST | |
|---|---|---|
| Market Cap | $2.17 billion | $10.99 billion |
| Revenue (TTM) | $54.85 million | $431.80 million |
| Net Income (TTM) | $-518,884,000 | $-136,717,000 |
TWST leads on 3 of 3 size & scale factors.
Valuation
| RXRX | TWST | |
|---|---|---|
| Price / Book | 2.37 | 24.67 |
| Price / Sales | 39.59 | 25.46 |
RXRX and TWST split the valuation factors evenly.
Profitability
| RXRX | TWST | |
|---|---|---|
| Net Margin | -945.92% | -31.66% |
| Return on Equity | -56.71% | -30.67% |
TWST leads on 2 of 2 profitability factors.
Risk & Sentiment
| RXRX | TWST | |
|---|---|---|
| Short Interest | 0.29% | 0.08% |
TWST leads on 1 of 1 risk & sentiment factors.
Dig deeper: RXRX overview, RXRX financials, TWST overview, TWST financials.
Comparisons use delayed, cached fundamental data and cover only the factors shown. For informational purposes only — not investment advice.